News

Stay up to date on the latest company news and scientific headlines.

Interleukin Genetics Announces Clinical Study to Evaluate Impact of PerioPredict® Genetic Risk Testing on Dental Patient Engagement and Preventative Care

Study aims to broaden evidence in support of medical and economic value of PerioPredict® genetic testing platform

WALTHAM, MA – March 29, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced Institutional Review Board (IRB) approval for a clinical study to assess the impact of the Company’s PerioPredict Genetic Risk Test on dental patient engagement for more preventive dental care. The study will build on Interleukin Genetics’ evidence base in support of the medical and economic value of the PerioPredict genetic testing platform.

PerioPredict identifies individuals at increased risk for severe periodontitis because they have a genetic tendency to over-produce chronic inflammation, […]

Interleukin Genetics Reports Fourth Quarter and Year-End 2015 Financial Results

Progress in Executing Commercial Plan Underscored by Recent Agreement with Metagenics, Inc.

Conference Call and Webcast Today at 8:30 a.m. EDT

WALTHAM, MA – March 17, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2015.
“2015 was an important year for Interleukin Genetics, as we focused on developing and executing a significantly updated strategic and operational plan centered on the medical value of our genetic test, PerioPredict®,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics. “We position PerioPredict as the cornerstone of enhanced benefits designs and employer-sponsored wellness initiatives to identify high-risk individuals for proactive outreach and personalized care. We believe these programs […]

Interleukin Genetics Appoints Global Clinical Advisory Board To Guide Enhanced Healthcare Through Targeted Management of Systemic Inflammation

World-renowned team to advise on building practical population health initiatives

 

WALTHAM, MA – March 16, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases that reduce longevity and life quality, today announced the appointment of leading experts to its newly formed Clinical Advisory Board to advise the Company on clinical programs aimed at demonstrating the clinical and health economic benefits of targeted prevention and treatment of periodontitis, a common local inflammatory disease, in the management of several chronic diseases that affect widespread tissues and organs of the body.

“We are extremely pleased to bring together a ‘dream team’ of international experts at the intersection of systemic and […]

Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results

WALTHAM, MA – March 15, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Thursday, March 17, 2016, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s fourth quarter and year-end 2015 financial results.

Thursday March 17th, 8:30 a.m. (ET)

Dial in (domestic):                  877-324-1976

Dial in (international):            631-291-4550

Conference ID:                        62665317

A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com.  The webcast will be archived following the call at www.ilgenetics.com. 

 

About Interleukin Genetics.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions.  The products empower individuals and their healthcare providers to manage […]

Interleukin Genetics and Metagenics Enter into Agreement to Incorporate PerioPredict® into Metagenics’ Employee Benefit Plan

WALTHAM, MA – February 18, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, and Metagenics, Inc., a global pioneer in science-based nutrition and wellness, today announced the signing of an agreement to provide Interleukin’s PerioPredict test to Metagenics’ employees as part of an enhanced employee benefits program.  PerioPredict will be used to identify individuals who may benefit from reduction of their systemic inflammatory burden as an approach to enhance prevention and management of chronic diseases.

Under the terms of the agreement, Interleukin will provide genetic testing and patient education to Metagenics employees, as well as dental professional support to their dental providers.

“We are […]

Interleukin Genetics Reports Third Quarter 2015 Financial Results

WALTHAM, Mass. – November 12, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal third quarter of 2015, ended September 30, 2015.

“Since joining Interleukin Genetics in April, I have been focused on developing a strategic and operational plan that will lay the groundwork for driving market adoption of PerioPredict®, our genetic test that identifies individuals with a life-long predisposition to over-produce inflammation.  Elevated inflammation is implicated in numerous chronic diseases.” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.

“We are encouraged by the reception of our enhanced positioning that outlines medical value for managing inflammation through practical dental interventions”, Mr. Carbeau continued.  “Medical studies now document the role of systemic inflammation in […]

Interleukin Genetics Reports Second Quarter 2015 Financial Results

Company to Host Conference Call Today at 8:30 a.m. ET

WALTHAM, Mass. – August 14, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal second quarter of 2015, ended June 30, 2015.

“Interleukin Genetics is advancing on its mission to prevent and more cost-effectively manage chronic diseases,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.  “We have enhanced the positioning of PerioPredict®, our genetic test that identifies individuals with a life-long predisposition to produce inflammation, to target patients with chronic conditions such as diabetes and cardiovascular disease who will benefit from increased dental care. Engaging these high-risk Individuals provides significant leverage to improve wellness and lower costs, builds on the strong foundation […]

Interleukin Genetics Announces Conference Call to Discuss Second Quarter 2015 Financial Results

WALTHAM, Mass. – August 7, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Friday, August 14, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s second quarter 2015 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company’s website at 52.2.148.42.  The webcast will be archived following the call at 52.2.148.42.

About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and […]

Interleukin Genetics and NYU School of Medicine Enter Into License Agreement to Enable Commercialization of a Genetics-Based Test for Osteoarthritis

New test will identify individuals at increased risk for progression of osteoarthritis, the most common adult joint disease

WALTHAM, MA and NEW YORK – July 15, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) and NYU School of Medicine announced today they signed a license agreement to develop the first  genetic test of its kind to identify individuals at increased risk for progression of osteoarthritis (OA) and related complications, such as knee replacement. The agreement pertains to U.S. patent application No. 12/435,260 titled “Detecting Genetic Predisposition to Osteoarthritis Associated Conditions,” which is jointly owned by NYU School of Medicine and Interleukin Genetics.

OA is the most common adult joint disease, increasing in frequency and severity in all aging populations. The estimated prevalence in […]

Interleukin Genetics to Present at 2015 Marcum MicroCap Conference

WALTHAM, MA – May 19, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced that Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics, will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015, at 2:30 p.m. (ET) at the Grand Hyatt New York in New York City.

The presentation will be webcast live and may be accessed at http://wsw.com/webcast/marcum3/iliu/index.aspx or by visiting the Company’s website at 52.2.148.42. The webcast will also be available on the Company’s website for a limited period of time following the conference.
 
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic […]